Format

Send to

Choose Destination
Vaccine. 2019 Apr 24;37(18):2477-2481. doi: 10.1016/j.vaccine.2019.03.045. Epub 2019 Apr 2.

Kinetics of maternally-derived serogroup A, C, Y and W-specific meningococcal immunoglobulin G in Malian women and infants.

Author information

1
Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, UK. Electronic address: helenfindlow@hotmail.com.
2
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA.
3
Centre pour le Développement des Vaccins, Bamako, Mali.
4
Department of Epidemiology, University of Maryland, Baltimore, MD, USA.
5
Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA.
6
Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, UK.

Abstract

A prospective, randomised, controlled observer-blind trial measuring the efficacy and immunogenicity of trivalent influenza vaccine (TIV) and the immunogenicity of quadrivalent meningococcal conjugate vaccine (MCV) in pregnant women and their infants up to 6 months of age was conducted in Mali. Here we reported the immunogenicity of MCV, which was used as a comparator vaccine to TIV, in this population. Third-trimester pregnant Malian women were randomized to receive TIV or MCV. Blood samples were collected from women prior to vaccination, 28 days post-vaccination, at delivery and 3 and 6 months post-delivery and from infants at birth and 3 and 6 months of age. Meningococcal-specific serogroup (Men) A, C, Y and W-specific antibodies were measured by enzyme linked immunosorbent assay in a randomly selected subset of 50 mother-infant pairs where the mother had received MCV. At birth, 94.0% (47/50) of infants had MenA specific IgG levels ≥ 2 µg/mL decreasing to 72.9% and 30.4% at 3 and 6 months of age. For MenC, 81.3% (39/48) of infants had MenC specific IgG levels ≥ 2 µg/mL at birth decreasing to 29.4% and 17.8% at 3 and 6 months of age. For MenY, 89.6% (43/48) of infants had MenY specific IgG levels ≥ 2 µg/mL at birth decreasing to 64.6% and 62.5% at 3 and 6 months of age. For MenW, 89.6% (43/48) of infants had MenW specific IgG levels ≥ 2 μg/ml at birth decreasing to 62.5% and 41.7% at 3 and 6 months of age. Maternal immunization with MCV conveyed protective levels of IgG at birth through to 3 months of age in the majority of infants.

KEYWORDS:

Maternal immunization; Meningococcal; Vaccination

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center